Ensuring Quality Outcomes in Hematologic Cancer Subgroups at EHA 2024
Experts discuss updated findings presented at the 2024 EHA Congress in diseases such as mantle cell lymphoma and acute myeloid leukemia.
Liso-cel May Show Benefit in Earlier Therapy Lines for Lymphoma Subgroups
Investigators must continue to explore the space for lisocabtagene maraleucel in mantle cell lymphoma, according to Manali Kamdar, MD.